|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | On theCAD of profiles for cutters and helical flutes-geometricalaspects显示文摘 | KALDOR S RAFAEL A M MESSINGER D | 1988 | CIRP Annals-Manufacturing Technology1988，37，1： | 1 |
| 3 | On the CAD of profiles for cutters and HeliealFluteS-geometrical aspects 显示文摘 | KALDOR S RAFAEL A M MESSINGER D | 1998 | Annals of the CIRP1998，37，1： | 1 |
| 4 | Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept显示文摘 | Faradji RN Tharavanij T Messinger S | 2008 | Transplantation2008，86，12： | 1 |
| 5 | Reticulocyte hemoglobin measurement--comparison of two methods in the diagnosis of iron-restricted erythropoiesis显示文摘 | Thomas L Franck S Messinger M | 2005 | Clin Chem Lab Med2005，43，11： | 1 |
| 6 | Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis 显示文摘 | Franek S Linssen J Messinger M | 2004 | Clin Chem2004，50，7： | 1 |
| 7 | On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment, subsequent I-IBsAg clearance in HBeAg-negative hepatitis B virus- infected patients treated with peginterferon alfa-2a 显示文摘 | Marcellin P Piratvisuth T Brunetto M Bonino F Farci P Yurdaydin C Gurel S Kapprell HP Messinger D Popescu M | 2010 | Hepatol Int2010，4，： | 1 |
| 8 | Reticulocyte hemoglobin measurement-comparison of two methods in the diagnosis of iron-restricted erythropoiesis 显示文摘 | Thomas L Franck S Messinger M | 2005 | Clin Chem Lab Med2005，43，11： | 1 |
| 9 | Transgenic analysis of GFAP promoter elements显示文摘 | Yeo S Bandyopadhyay S Messing A | | 0，，09： | 1 |
| 10 | Reticulocyte hemoglobin measurement--comparison of two methods in the diagnosis of iron-restricted erythropoiesis显示文摘 | Thomas L Franck S Messinger M | | 0，，11： | 1 |
| 11 | Toward maximizing the success rates of human islet isolation:influence of donor and isolation factors 显示文摘 | Ponte GM Pileggi A Messinger S | 2007 | Cell Transplant2007，16，59： | 1 |
| 12 | Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis显示文摘 | Franck S Linssen J Messinger M | | 0，，07： | 1 |
| 13 | First and early second trimester fetal heart screening显示文摘 | Yagel S Cohen SM Messing B | | 0，，02： | 1 |
| 14 | Antiproinflammatory effects of iodixanol (OptiPrep) -based density gradient purification on human islet preparations显示文摘 | Mita A Ricordi C Messinger S | 2010 | Cell Transplant2010，19，12： | 1 |
| 15 | Alterations of the female reproductive system in islet recipient receiving immunosuppression显示文摘 | Del Olmo Garcia MI Lauriola V Gomez Aracena A Messinger S Corrales A Ricordi C | | 0，，： | 1 |
| 16 | Improved Long-Term Health-Related Quality of Life After Islet Transplantation 显示文摘 | Tharavanij T Betancourt A Messinger S | 2008 | Transplantation2008，86，9： | 1 |
| 17 | Centrosome and microtubule dynamics during meiotic progression in the mouse oocyte显示文摘 | MESSINGER S M ALERTINI D F | 1991 | J Cell Sci1991，100，： | 1 |
| 18 | Anticipatory smiling:Linking early affective communication and social outcome显示文摘 | Parlade M V Messinger D S Delgado F | | 0，，： | 1 |
| 19 | HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care显示文摘 | Metsch LR Pereyra M Messinger S | 2008 | HIV/AIDS CID2008，47，15： | 1 |
| 20 | Early metabolic markers of islet allograft dysfunction显示文摘 | Baidal DA Faradji RN Messinger S | 2009 | Transplantation2009，87，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员